OBJECTIVES: To compare anti-inflammatory effect of @entity2993 and @entity8671 in @entity1 of @entity1187 . MATERIALS AND METHODS: The study was a prospective, open-labeled, randomized and single-center study conducted on 100 @entity1 of @entity1187 . @entity1 were assigned to @entity2993 40 mg daily or @entity8671 20 mg daily for 4 weeks. @entity1851 ( @entity1851 ) levels, lipid profiles, erythrocyte sedimentation rate (ESR) and adverse effects were measured at beginning and at the end of 4 weeks. RESULTS: Baseline parameters and clinical profile did not differ between the two groups. @entity1851 levels significantly decreased from beginning to the end of 4 weeks in both @entity2993 and @entity8671 groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). However, there was significant difference between the levels of @entity1851 in @entity1 of the @entity8671 group as compared to the @entity2993 group (19.91    6.32 vs 23.07    7.47, P < 0.05). In addition, both the drugs were associated with a reduction in total @entity165 , LDL levels and ESR at the end of 4 weeks as compared to the beginning (P < 0.001 for all comparisons). CONCLUSION: Both @entity2993 (40 mg) and @entity8671 (20 mg) are effective in decreasing @entity1851 and LDL @entity165 levels even in a short duration of 4 weeks. @entity8671 was found to be more effective in decreasing @entity1851 levels.

Comparison of anti-inflammatory effect of XXXX with @entity8671 in @entity1 of @entity1187 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndrome'] @entity8671 :: ('MESH:C422923', 'Chemical') :: ['rosuvastatin', 'Rosuvastatin'] @entity2993 :: ('MESH:C065179', 'Chemical') :: ['atorvastatin'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']
@entity2993 :: (MESH:C065179,Chemical) :: ['atorvastatin']
